A double-blind, placebo-controlled study of adjunctive calcitonin nasal spray in acute refractory mania

Bipolar Disorders

Volumn 15, Issue 4, 2013, Pages 359-364

  Vik, Astrid ^a   Ravindran, Arun ^b   Shiah, I Shin ^c   Wong, Hubert ^a   Walji, Nazlin ^a   Lam, Raymond W ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Bipolar disorder; Calcitonin; Nasal spray; Refractory mania

Indexed keywords

CALCITONIN; MOOD STABILIZER; NEUROLEPTIC AGENT; SODIUM CHLORIDE; NOSE SPRAY; TRANQUILIZER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; FEMALE; HUMAN; MALE; MANIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG MONITORING; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CALCITONIN; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL SPRAYS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; TREATMENT OUTCOME;

EID: 84878939563     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12062     Document Type: Article

References (15)

1. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
2. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 (Suppl. 3): 5-69.
3. Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255.
4. Yatham LN. Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am 2005; 28: 325-347.
5. Ketter TA. Combination therapy versus monotherapy in bipolar disorder. J Clin Psychiatry 2008; 69: e34.
6. Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-764.
7. Vik A, Yatham LN. Calcitonin and bipolar disorder: a hypothesis revisited. J Psychiatry Neurosci 1998; 23: 109-117.
8. Carman JS, Wyatt RJ. Use of calcitonin in psychotic agitation or mania. Arch Gen Psychiatry 1979; 36: 72-75.
9. Carman JS, Wyatt ES, Smith W et al. Calcium and calcitonin in bipolar affective disorder. In: Post RM, Ballenger JC eds. Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins, 1984: 340-355.
10. Hough C, Lu SJ, Davis CL, Chuang DM, Post RM. Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry 1999; 46: 247-255.
11. Dubovsky SL, Murphy J, Thomas M, Rademacher J. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 1992; 149: 118-120.
12. Dubovsky SL, Murphy J, Christiano J, Lee C. The calcium second messenger system in bipolar disorders: data supporting new research directions. J Neuropsychiatry Clin Neurosci 1992; 4: 3-14.
13. Berk M, Bodemer W, van Oudenhove T, Butkow N. Dopamine increases platelet intracellular calcium in bipolar affective disorder and controls. Int Clin Psychopharmacol 1994; 9: 291-293.
14. Levy NA, Janicak PG. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord 2000; 2: 108-119.
15. Mallinger AG, Thase ME, Haskett R et al. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord 2008; 10: 856-866.